当前位置:首页 - 行情中心 - *ST目药(600671) - 财务分析 - 利润表

*ST目药

(600671)

  

流通市值:11.13亿  总市值:11.13亿
流通股本:1.22亿   总股本:1.22亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入86,107,172.1950,953,892.5122,252,900.21108,906,179.08
营业收入86,107,172.1950,953,892.5122,252,900.21108,906,179.08
二、营业总成本106,559,302.7266,993,515.1230,681,040.64145,639,100.97
营业成本66,487,209.9539,444,703.9917,676,941.4483,929,783.75
税金及附加627,686.83252,683.69-138,458.24954,952.26
销售费用2,199,164.743,357,791.421,884,348.146,067,316.82
管理费用31,837,059.3320,630,205.899,722,239.2345,700,354.6
研发费用442,956.331,371.681,371.681,584,081.57
财务费用4,965,225.543,306,758.451,534,598.397,402,611.97
其中:利息费用4,676,562.583,318,818.931,574,568.667,404,500.96
其中:利息收入34,125.6331,150.4281,827.9350,794.49
加:投资收益-525,926.17--964,806.44
资产处置收益61,292.0461,292.04--
资产减值损失(新)-7,338,136.86-6,634,422.79--27,330,364
信用减值损失(新)5,016,721.171,520,611.62-97,125.36-7,681,052.06
其他收益517,428.41405,520.85224,154.52897,014.54
营业利润平衡项目0000
四、营业利润-22,720,751.94-20,686,620.89-8,301,111.27-69,882,516.97
加:营业外收入3,419,879.792,431,408.431,181,506.3810,388,381.72
减:营业外支出8,225,139.735,387,800.652,854,269.2812,871,511.74
利润总额平衡项目0000
五、利润总额-27,526,011.88-23,643,013.11-9,973,874.17-72,365,646.99
减:所得税费用114.46114.46-842,171.14
六、净利润-27,526,126.34-23,643,127.57-9,973,874.17-73,207,818.13
持续经营净利润-27,526,126.34-23,643,127.57-9,973,874.17-73,207,818.13
归属于母公司股东的净利润-27,457,999.53-23,421,041.86-9,055,100.93-67,560,283.78
少数股东损益-68,126.81-222,085.71-918,773.24-5,647,534.35
(一)基本每股收益-0.23-0.19-0.07-0.55
(二)稀释每股收益-0.23-0.19-0.07-0.55
九、综合收益总额-27,526,126.34-23,643,127.57-9,973,874.17-73,207,818.13
归属于母公司股东的综合收益总额-27,457,999.53-23,421,041.86-9,055,100.93-67,560,283.78
归属于少数股东的综合收益总额-68,126.81-222,085.71-918,773.24-5,647,534.35
公告日期2023-10-282023-08-312023-04-262023-04-26
审计意见(境内)带强调事项段的无保留意见
TOP↑